Table 2.
Significant associations of mutations, copy number aberrations and mRNAexpression of angiogenesis related genes
| Genomic change | No genomic change | p value | |
|
| |||
| Site | TP53 mut | TP53 wt | |
| ECC | 0 | 14 (100%) | <0.001 |
| GBC | 23 (43%) | 31 (57%) | |
| ICC | 2 (15%) | 11 (85%) | |
| Site | PRKAR1A copy gain | PRKAR1A no gain | |
| ECC & GBC | 26 (45%) | 32 (55%) | 0.007 |
| ICC | 10 (91%) | 1 (9%) | |
| Sex | CTNNB1 mut | CTNNB1 wt | |
| Men | 20 (49%) | 21 (51%) | 0.017 |
| Women | 7 (21%) | 26 (79%) | |
| PTEN | CTNNB1 mut | CTNNB1 wt | |
| Mutated (mut) | 17 (63%) | 6 (14%) | <0.001 |
| Wild-type (wt) | 10 (37%) | 38 (86%) | |
| Age | KIT mut | KIT wt | |
| ≥68 yrs | 6 (15%) | 35 (85%) | 0.028 |
| <68 yrs | 0 | 35 (100%) | |
|
| |||
| mRNA RQ positive | mRNA RQ negative | ||
|
| |||
| Nuclear β-catenin | EDNRB | ||
| Positive | 15 (40%) | 9 (75%) | 0.047 |
| Negative | 23 (60%) | 3 (25%) | |
| Nuclear β-catenin | FLT4 | ||
| Positive | 6 (25%) | 18 (69%) | 0.002 |
| Negative | 18 (75%) | 8 (31%) | |
| Nuclear β-catenin | VEGFC | ||
| Positive | 4 (20%) | 19 (59%) | 0.009 |
| Negative | 16 (80%) | 13 (41%) | |
| CTNNB1 | EDNRB | ||
| Mutated | 10 (25%) | 7 (70%) | 0.021 |
| Wild-type | 30 (75%) | 3 (30%) | |
| PIK3R1 | EDNRA | ||
| Mutated | 5 (17%) | 5 (6%) | 0.032 |
| Wild-type | 25 (83%) | 4 (44%) | |
| PTEN | EDNRA | ||
| Mutated | 7 (20%) | 7 (70%) | 0.005 |
| Wild-type | 28 (80%) | 3 (30%) | |
| PIK3CA | EDN1 | ||
| Mutated | 9 (27%) | 0 | 0.010 |
| Wild-type | 24 (73%) | 20 (100%) | |
| ERBB2 | FLT4 | ||
| Copy gain | 10 (36%) | 2 (9%) | 0.045 |
| No copy gain | 18 (64%) | 20 (91%) | |
ICC, ECC: intra- and extrahepatic cholangiocarcinoma, respectivley; GBC: gallbladder carcinoma; RQ: relative quantification value.